Catheter-Directed Clot Busting Cuts Pulmonary Embolism Collapse Risk by 61%
A landmark NEJM trial shows ultrasound-assisted fibrinolysis plus anticoagulation dramatically outperforms anticoagulation alone in intermediate-risk PE.
Summary
The HI-PEITHO trial, published in NEJM, randomized 544 patients with intermediate-risk pulmonary embolism to ultrasound-facilitated, catheter-directed fibrinolysis plus anticoagulation versus anticoagulation alone. Within 7 days, the composite primary outcome — PE-related death, cardiorespiratory decompensation or collapse, or symptomatic PE recurrence — occurred in just 4.0% of the intervention group versus 10.3% of controls, a 61% relative risk reduction. Major bleeding rates were low and statistically similar between groups, and no intracranial hemorrhage occurred. These findings challenge the standard of anticoagulation alone for this patient population and support more aggressive early intervention in carefully selected intermediate-risk PE patients.
Detailed Summary
Pulmonary embolism (PE) remains a leading cause of cardiovascular death, yet the optimal treatment strategy for intermediate-risk (submassive) PE — patients who are hemodynamically stable but show signs of right heart strain — has long been debated. Anticoagulation is standard care, but whether it adequately prevents early deterioration is uncertain.
The HI-PEITHO trial addressed this gap in a multinational, adaptive-design randomized controlled trial with blinded outcome adjudication. Patients enrolled had intermediate-risk PE confirmed by right-to-left ventricular diameter ratio ≥1.0, elevated troponin, and at least two signs of cardiorespiratory distress. They were randomized to ultrasound-facilitated, catheter-directed fibrinolysis (USCDF) with alteplase plus anticoagulation, or anticoagulation alone.
Among 544 patients, the 7-day composite primary outcome occurred in 4.0% of the intervention group versus 10.3% of controls — a relative risk of 0.39 (95% CI 0.20–0.77; P=0.005). The benefit was driven predominantly by a reduction in cardiorespiratory decompensation or collapse. Critically, major bleeding rates were not significantly different (4.1% vs 2.2% at 7 days; P=0.32), and no intracranial hemorrhage was observed in either group.
These results are clinically significant because they suggest that the targeted, catheter-based delivery of low-dose thrombolytics achieves meaningful clot reduction without the systemic bleeding risks historically associated with full-dose systemic thrombolysis. The USCDF approach may offer a favorable therapeutic window for this vulnerable population.
Caveats include industry funding by Boston Scientific (maker of the EKOS device used), the relatively short 7-day primary endpoint, and the need for longer-term follow-up data on functional outcomes and chronic thromboembolic complications.
Key Findings
- 7-day composite adverse outcome occurred in 4.0% vs 10.3% favoring USCDF plus anticoagulation (RR 0.39, P=0.005).
- Benefit was driven primarily by fewer cardiorespiratory decompensation or collapse events in the intervention group.
- Major bleeding rates were low and not significantly different between groups at 7 or 30 days.
- No intracranial hemorrhage occurred in either group across the entire 30-day follow-up period.
- Trial enrolled intermediate-risk PE patients with RV/LV ratio ≥1.0, elevated troponin, and cardiorespiratory distress signs.
Methodology
HI-PEITHO was a multinational, adaptive-design randomized controlled trial of 544 patients with intermediate-risk PE, comparing USCDF plus anticoagulation to anticoagulation alone. Outcome adjudication was blinded, and the primary composite endpoint was assessed at 7 days. The trial was funded by Boston Scientific and registered at ClinicalTrials.gov (NCT04790370).
Study Limitations
The trial was funded by Boston Scientific, the manufacturer of the EKOS ultrasound-facilitated catheter system, introducing potential industry bias. The primary endpoint was limited to 7 days, leaving longer-term outcomes such as chronic thromboembolic pulmonary hypertension and functional capacity unaddressed. Generalizability may be limited to centers with interventional PE expertise.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.